Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

About this update from Sagimet Biosciences Inc. - Series A

SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the 8th Annual Evercore ISI Healthcare Conference on Tuesday, December 2, 2025, in Coral Gables, Florida, with a fireside chat at 12:55pm ET (link here ). A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at  www.sagimet.com , with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom is currently being tested in a Phase 1 PK clinical trial and is planned to be developed for cirrhotic patients living with F4-stage MASH. TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit  www.sagimet.com . Investor Contact: Joyce Allaire  LifeSci Advisors  [email protected] Media Contact: Michael Fitzhugh LifeSci Advisors  [email protected]

View stock analysis, news, and events for Sagimet Biosciences Inc. - Series A